Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

GB:CURE ETF Forecast & Price Targets

Compare
See the Price Targets and Ratings of:

GB:CURE Analyst Ratings

Moderate Buy
49ConsensusRatings
41Buy8Hold0Sell
Based on the Wall Street analyst consensus for 49 of GB:CURE’s holdings.

GB:CURE 12 Month Forecast

$33.30â–²(20.65% Upside)
Based on Wall Street analyst 12-month price targets for 49 of VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s holdings in the last 3 months. The average price target is $33.30 with a high forecast of $43.09 and a low forecast of $24.20. The average price target represents a 20.65% change from the last price of $27.60.
Highest Price Target$43.09Average Price Target$33.30Lowest Price Target$24.20

GB:CURE Stocks With Highest Upside Potential

GB:CURE highest upside
NamePrice & ChangeAnalyst ConsensusAnalyst Price Target
Strong Buy$73.22(159.75% Upside)
Strong Buy$108.40(121.22% Upside)
Moderate Buy$310.55(104.79% Upside)
Strong Buy$49.31(96.05% Upside)
Strong Buy$46.43(92.97% Upside)

GB:CURE Stocks With Highest Downside Potential

GB:CURE highest downside
NamePrice & ChangeAnalyst ConsensusAnalyst Price Target
Hold$145.38(-42.04% Downside)
Hold$29.91(-7.74% Downside)
Hold$8.88(-0.73% Downside)
Moderate Buy$50.73(0.44% Upside)
Moderate Buy$13.30(1.29% Upside)

GB:CURE ETF FAQ

What is GB:CURE’s average 12-month price target, according to analysts?
Based on Wall Street analyst price targets for 49 of GB:CURE’s holdings, VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s 12-month average price target is $33.30.
What is GB:CURE’s upside potential, based on the analysts’ average price target?
GB:CURE’s average price target of $33.30 represents a 20.65% upside from its last price of $27.60.
Is GB:CURE a Buy, Sell or Hold?
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD has a consensus rating of Moderate Buy, based on the analyst consensus for 49 of GB:CURE’s holdings: 41 rated Buy, 8 rated Hold and 0 rated Sell.
What is VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD’s price target?
The average price target for VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD is $33.30, based on Wall Street analyst 12-month price targets for 49 of GB:CURE’s holdings, issued in the past 3 months. The highest price target is $43.09 and the lowest is $24.20. The average price target represents a 20.65% increase from the last price of $27.60.
What is GB:CURE’s expense ratio?
GB:CURE’s expense ratio is 0.35%.
How many holdings does GB:CURE have?
GB:CURE holds 50 assets.
How can I buy shares of GB:CURE?
You can buy shares of GB:CURE through a brokerage account. Compare brokers on our Best Online Brokers page.